Dysregulation of cyclin dependent kinase
6 expression in splenic marginal zone lymphoma through chromosome 7q translocations.
Cyclin dependent kinases
as targets for cancer therapy.
United States Patent 6,531,479 relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
Cyclin Dependent Kinase (CDK) Inhibitors are a novel class of drugs that act on the same CDK enzyme targets as the body's own cancer stopping genes.
Healthcare company Pfizer Inc (NYSE:PFE) announced on Wednesday that its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases
(CDK) 4 and 6, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.
The second patent application includes claims for assays that evaluate the carcinogenicity (cancer causing activity) of potential carcinogens or mutagens by monitoring the levels of markers of cellular hyper-proliferation called "cyclin dependent kinases", or "CDK's"
Paracelsian's team of scientists discovered that there is a consistent relationship between cyclin dependent kinase concentrations and cell growth and proliferation.